

# Christine Ranney

Partner

[cranney@gibsondunn.com](mailto:cranney@gibsondunn.com)

T: +1 303.298.5720

Denver

Christine Ranney is a partner in the Denver office and a member of the firm's Intellectual Property Practice Group. She focuses on patent and appellate litigation and is knowledgeable across a range of arts and practices, including pharmaceuticals, biotechnology, consumer goods, software, and telecommunications. Christine has experience in all phases of litigation from pre-suit diligence to appeal, including managing discovery, taking and defending depositions, working with experts, drafting dispositive motions, arguing discovery motions, Markman hearings, and pre- and post-trial motions, conducting direct and cross-examination of expert witnesses at trial, and drafting appellate briefs. She has participated in two ANDA bench trials, an ITC trial, and a jury trial, and secured favorable results for her clients in each, including most recently in two multi-billion dollar biotech litigations. She also has substantial experience handling proceedings before the Patent Trial and Appeal Board, including inter partes review and post-grant review petitions, often in parallel with ongoing high-stakes litigation.

Christine is recognized by *Best Lawyers: Ones to Watch® in America* for Appellate Practice, Life Sciences Practice, and Litigation – Patent and has been listed in the publication since 2022. *Managing IP Handbook* named Christine as a Rising Star in their 2021 edition, and the *Denver Business Journal* named her to their 40 Under 40 class of 2025.

Representative matters:

- Secured one of the largest defense victories in patent litigation history for clients EMD Serono, Inc. and Pfizer Inc. in a suit brought by Biogen MA Inc. seeking more than \$5.4 billion in damages for infringement of a patent relating to the use of recombinant DNA technology in the treatment of Multiple Sclerosis
- Obtained favorable bench ruling and Federal Circuit affirmance for Novartis Pharmaceuticals Corporation in litigation enforcing patent covering Novartis's \$3 billion Multiple Sclerosis drug GILENYA®
- Obtained critical victory for Assertio Therapeutics, Inc. (formerly Depomed, Inc.) in Hatch-Waxman litigation concerning Assertio's most important asset, the opioid drug NUCYNTA®
- Represented Uber in multiple patent infringement litigations in the Eastern and Western Districts of Texas, obtaining transfer to California in one and favorable resolutions in others
- Secured favorable final determination for client Fitbit on patent and trade secret allegations brought before the International Trade Commission.

Prior to joining the firm, she served as a law clerk to the Honorable Pauline Newman of the U.S. Court of Appeals for the Federal Circuit. Before her clerkship, she was an analyst in a leadership development program at Merck & Co. Christine received her Juris Doctor, *cum*



## Capabilities

Intellectual Property  
Life Sciences

## Credentials

### Education

New York University - 2013 Juris Doctor  
Princeton University - 2008 BS in Engineering

### Admissions

California Bar  
Colorado Bar

### Clerkships

US Court of Appeals, Federal Circuit, Hon. Pauline Newman, 2013 - 2015

*laude*, from New York University School of Law in 2013. She earned her Bachelor of Science in Engineering, in Chemical Engineering, in 2008 from Princeton University.

Christine is admitted to practice law in the States of California and Colorado and before the U.S. Court of Appeals for the Federal Circuit.

## **Christine Ranney**

Partner

[cranney@gibsondunn.com](mailto:cranney@gibsondunn.com)

T: +1 303.298.5720

Denver